Peripheral Arterial Occlusive Disease
- Author: Vincent Lopez Rowe, MD; Chief Editor: Vincent Lopez Rowe, MD more...
Background
Claudication, which is defined as reproducible ischemic muscle pain, is one of the most common manifestations of peripheral vascular disease caused by atherosclerosis. Claudication occurs during physical activity and is relieved after a short rest. Pain develops because of inadequate blood flow.
Pathophysiology
Single or multiple arterial stenoses produce impaired hemodynamics at the tissue level in patients with peripheral arterial occlusive disease (PAOD), shown below. Arterial stenoses lead to alterations in the distal pressures available to affected muscle groups and to blood flow.
Peripheral arterial occlusive disease. This angiogram shows a superficial femoral artery occlusion on one side (with reconstitution of the suprageniculate popliteal artery) and superficial femoral artery stenosis on the other side. This is the most common area for peripheral vascular disease. Under resting conditions, normal blood flow to extremity muscle groups averages 300-400 mm/min. Once exercise begins, blood flow increases up to 10-fold owing to the increase in cardiac output and compensatory vasodilation at the tissue level. When exercise ceases, blood flow returns to normal within minutes.
In patients with PAOD, resting blood flow is similar to that of a healthy person. However, during exercise, blood flow cannot maximally increase in muscle tissue because of proximal arterial stenoses. When the metabolic demands of the muscle exceed blood flow, claudication symptoms ensue. At the same time, a longer recovery period is required for blood flow to return to baseline once exercise is terminated.
Similar abnormal alterations occur in distal perfusion pressure in affected extremities. In normal extremities, the mean blood pressure drop from the heart to the ankles is no more than a few millimeters of mercury. In fact, as pressure travels distally, the measured systolic pressure actually increases because of the higher resistance encountered in smaller-diameter vessels.
At baseline, a healthy person may have a higher measured ankle pressure than arm pressure. When exercise begins, no change in measured blood pressure occurs in the healthy extremity.
In the atherosclerotic limb, each stenotic segment acts to reduce the pressure head experienced by distal muscle groups. Correspondingly, at rest, the measured blood pressure at the ankle is less than that of a healthy person. Once physical activity starts, the reduction in pressure produced by the atherosclerotic lesion becomes more significant and the distal pressure is greatly diminished.
The phenomenon of increased blood flow causing decreased pressure distally to an area of stenosis is a matter of physics. Poiseuille calculated energy losses across areas of resistance with varying flow rates by using the following equation, in which Q is flow, v is viscosity, L is the length of the stenotic area, r is the radius of the open area within the stenosis, and k is constant:
Resistance = pressure = Q8vL/kr4
Applying this equation, the pressure gradient is directly proportional to the flow and length of stenosis and inversely proportional to the fourth power of the radius.
Therefore, while increasing the rate of flow directly increases the pressure gradient at any given radius, these effects are much less marked than those due to changes in the radius of the stenosis.
As the radius is raised to the fourth power, it has the most dramatic impact on a pressure gradient across a lesion. This impact is additive when 2 or more occlusive lesions are located sequentially within the same artery.
Epidemiology
Frequency
United States
Atherosclerosis affects up to 10% of the Western population older than 65 years. With the elderly population expected to increase 22% by the year 2040, atherosclerosis is expected to have a huge financial impact on medicine. When claudication is used as an indicator, estimates are that 2% of the population aged 40-60 years and 6% older than 70 years are affected.
Mortality/Morbidity
The most feared consequence is severe limb-threatening ischemia leading to amputation. However, studies of large patient groups with claudication reveal that amputation is uncommon. Boyd prospectively followed 1440 patients with intermittent claudication for as long as 10 years and reported that only 12.2% required amputation.[1] In the Framingham study, only 1.6% of patients with claudication reached the amputation stage after 8.3 years of follow-up.
- Limb amputation largely depends on the number and severity of cardiovascular risk factors (ie, smoking, hypertension, diabetes). Continued smoking has been identified as the most consistent adverse risk factor associated with the progression of peripheral arterial occlusive disease (PAOD). Other factors are the severity of disease at the time of the initial patient encounter and, in some studies, the presence of diabetes.
- As with most patients with vascular disease, survival is less than that of age-matched control groups. Coronary artery disease with a subsequent myocardial event is the major contributor to outcome. Predicted mortality rates for patients with claudication at 5, 10, and 15 years of follow-up are approximately 30%, 50%, and 70%, respectively.
Race
- Peripheral arterial occlusive disease (PAOD) has no racial predilection.
Sex
- Intermittent claudication most commonly manifests in men older than 50 years.
- Although younger patients may present with symptoms consistent with intermittent claudication, other etiologies of leg pain and claudication (eg, popliteal entrapment syndrome) must be strongly considered.
Boyd AM. The natural course of arteriosclerosis of the lower extremities. Angiology. 1960;11:10.
Conen D, Everett BM, Kurth T, et al. Smoking, smoking status, and risk for symptomatic peripheral artery disease in women: a cohort study. Ann Intern Med. Jun 7 2011;154(11):719-26. [Medline]. [Full Text].
Dhangana R, Murphy TP, Coll JR, Ahn SH, Zafar AM, Qadeer FF, et al. Prevalence of abnormal ankle-brachial index among individuals with low or intermediate framingham risk scores. J Vasc Interv Radiol. Aug 2011;22(8):1077-82. [Medline].
[Best Evidence] Monaco M, Stassano P, Di Tommaso L, Pepino P, Giordano A, Pinna GB, et al. Systematic strategy of prophylactic coronary angiography improves long-term outcome after major vascular surgery in medium- to high-risk patients: a prospective, randomized study. J Am Coll Cardiol. Sep 8 2009;54(11):989-96. [Medline].
O'Donnell ME, Badger SA, Sharif MA, Young IS, Lee B, Soong CV. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. J Vasc Surg. May 2009;49(5):1226-34. [Medline].
Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, Lindholt JS. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg. Oct 2009;38(4):463-74. [Medline].
Samson RH. The role of statin drugs in the management of the peripheral vascular patient. Vasc Endovascular Surg. Aug-Sep 2008;42(4):352-66. [Medline].
Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. Apr 2007;45(4):645-654; discussion 653-4. [Medline].
Cassar K, Bachoo P, Ford I, et al. Platelet activation is increased in peripheral arterial disease. J Vasc Surg. Jul 2003;38(1):99-103. [Medline].
Clifford PC, Davies PW, Hayne JA, Baird RN. Intermittent claudication: is a supervised exercise class worth while?. Br Med J. Jun 21 1980;280(6230):1503-5. [Medline].
Collins TC, Petersen NJ, Suarez-Almazor M, Ashton CM. The prevalence of peripheral arterial disease in a racially diverse population. Arch Intern Med. Jun 23 2003;163(12):1469-74. [Medline].
Couch NP. On the arterial consequences of smoking. J Vasc Surg. May 1986;3(5):807-12. [Medline].
Cronenwett JL, Warner KG, Zelenock GB, et al. Intermittent claudication. Current results of nonoperative management. Arch Surg. Apr 1984;119(4):430-6. [Medline].
Ekroth R, Dahllof AG, Gundevall B, et al. Physical training of patients with intermittent claudication: indications, methods, and results. Surgery. Nov 1978;84(5):640-3. [Medline].
Green RM, McNamara J. The effects of pentoxifylline on patients with intermittent claudication. J Vasc Surg. Feb 1988;7(2):356-62. [Medline].
Hughson WG, Mann JI, Garrod A. Intermittent claudication: prevalence and risk factors. Br Med J. May 27 1978;1(6124):1379-81. [Medline].
Jonason T, Ringqvist I. Factors of prognostic importance for subsequent rest pain in patients with intermittent claudication. Acta Med Scand. 1985;218(1):27-33. [Medline].
Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc. Jan 1985;33(1):13-8. [Medline].
Kannel WB, Skinner JJ, Schwartz MJ, Shurtleff D. Intermittent claudication. Incidence in the Framingham Study. Circulation. May 1970;41(5):875-83. [Medline].
Porter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J. Jul 1982;104(1):66-72. [Medline].
Reid DD, Brett GZ, Hamilton PJ, et al. Cardiorespiratory disease and diabetes among middle-aged male Civil Servants. A study of screening and intervention. Lancet. Mar 23 1974;1(7856):469-73. [Medline].
Rosenbloom MS, Flanigan DP, Schuler JJ, et al. Risk factors affecting the natural history of intermittent claudication. Arch Surg. Jul 1988;123(7):867-70. [Medline].
Rowe VL, Lee W, Weaver FA, Etzioni D. Patterns of treatment for peripheral arterial disease in the United States: 1996-2005. J Vasc Surg. Apr 2009;49(4):910-7. [Medline].
Vogt MT, Wolfson SK, Kuller LH. Lower extremity arterial disease and the aging process: a review. J Clin Epidemiol. May 1992;45(5):529-42. [Medline].
Walsh DB, Gilbertson JJ, Zwolak RM, et al. The natural history of superficial femoral artery stenoses. J Vasc Surg. Sep 1991;14(3):299-304. [Medline].

